Correction to: Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)

Andreas Pinter, Antonio Costanzo, Sanjay Khattri, Stephen D. Smith, J.m. Carrascosa, Yayoi Tada, Elisabeth Riedl, Adam Reich, Alan Brnabic, Natalie Haustrup, Anastasia Lampropoulou, Ilya Lipkovich, Zbigniew Kadziola, C. Paul, Christopher SchusterDermatology 2024 · DOI · OpenAlex

This document serves as a formal correction (erratum) to the previously published 12-month outcomes of the PSoHO study. While the core findings remain robust, this update provides essential clarifications regarding study design, outcome definitions, and statistical transparency to ensure the data is accurately interpreted by the clinical community.

Clarifying Study Design: A Prospective Approach

A significant update in this correction is the formal classification of the PSoHO study as prospective. In clinical research, a prospective observational study is planned before data collection begins, which generally offers higher evidentiary value than retrospective chart reviews. This distinction is vital for researchers and meta-analysts evaluating the strength of the real-world evidence provided by PSoHO.

Standardizing Outcome Definitions

To ensure reproducibility and clear comparison between different biologic treatments (such as IL-17 and IL-23 inhibitors), the authors have refined the definitions for "effectiveness" and "durability." These metrics serve as the benchmarks for success in the study.

Definitions for Effectiveness and Quality of Life outcomes.

As shown in the updated definitions, Effectiveness is primarily measured by:

  • Primary Outcome: Achieving at least a 90% improvement in the Psoriasis Area and Severity Index (PASI90) or a static Physician’s Global Assessment (sPGA) score of 0 or 1.
  • Quality of Life: Measured by the Dermatology Life Quality Index (DLQI), targeting a score of 0 or 1, indicating the disease no longer impacts the patient's life.

Beyond initial success, the study emphasizes Durability, which requires patients to maintain their response over time.

Definitions for Durability of Effectiveness outcomes.

To meet the "Durability of Effectiveness" outcome, a patient must meet the primary criteria at week 12 and subsequently maintain specific improvement thresholds (like PASI75 or a 2-point sPGA improvement) through the 12-month mark.

Refining "Super Responder" Terminology

The correction also addresses the terminology used for "super responders"—patients who exhibit an exceptional response to biologic therapy. The authors removed the word "weight" in this context and updated citations to reflect the latest literature (e.g., Mastorino et al., 2022; Ruiz-Villaverde et al., 2022). This ensures that the discussion surrounding high-performing patients is grounded in current clinical understanding.

Conclusion and Significance

The primary "result" of this correction is the provision of a previously missing statistical appendix and the finalized definitions of study endpoints. By standardizing these metrics and clarifying the prospective nature of the trial, the authors enhance the transparency and utility of the PSoHO dataset. This real-world evidence remains a critical tool for understanding how biologics perform in everyday clinical practice across diverse patient populations.

Summary updated

Abstract

The authors would like to share the following corrections to their publication: The email address of the corresponding author was updated to "[email protected]". On page 1, the words 'Clinicaltrial.gov identifier' were removed. In the Introduction, the word 'prospective' was added to describe PSoHO. In relation to super responders, the word 'weight' was removed and the incorrect citations of 13-15 were corrected. Mastorino L, Susca S, Cariti C, et al. "Superresponders" at biologic treatment for psoriasis: a comparative study among IL17 and Il23 inhibitors. Exp Dermatol. 2022;32:2187-8. Ruiz-Villaverde R, Vasquez-Chinchay F, Rodriguez-Fernandez-Freire L, et al. Super-responders in moderate-severe psoriasis under guselkumab treatment: myths, realities and future perspectives. Life. 2022;12:1412. Schäkel K, Reich K, Asadullah K, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 37(10):2016-27. The layout of Table 1 was updated for clarity and the statistical appendix is now provided. (Table presented.) Outcomes Definition Primary outcome Patients who achieved (a) At least a 90% improvement in the PASI score (PASI90), or (b) A score of 0 or 1 in sPGA, or (c) Both outcomes PASI100 Patients who achieved 100% improvement in the PASI score PASI90 Patients who achieved at least a 90% improvement in the PASI score DLQI (0,1) Patients with an available DLQI score of 2 or greater at baseline and who subsequently achieved a DLQI score of 0 or 1 Durability of effectiveness outcome Patients who met the primary outcome at week 12 and who subsequently at months 6 and 12 achieved an improvement of (a) At least a 75% in PASI score (PASI75), or (b) 2 or more points in sPGA score from baseline, or (c) Both outcomes PASI100 durability outcome Patients who achieved PASI100 at week 12 and then maintained PASI100 at both months 6 and 12 PASI90 durability outcome Patients who achieved PASI90 at week 12 and then maintained at least PASI90 at both months 6 and 12 The original article has been corrected.
BibTeX
@inproceedings{pinter2024correction,
  author = {Andreas Pinter and Antonio Costanzo and Sanjay Khattri and Stephen D. Smith and J.M. Carrascosa and Yayoi Tada and Elisabeth Riedl and Adam Reich and Alan Brnabic and Natalie Haustrup and Anastasia Lampropoulou and Ilya Lipkovich and Zbigniew Kadziola and C. Paul and Christopher Schuster},
  title = {{Correction to: Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)}},
  booktitle = {Dermatology},
  year = {2024},
  doi = {10.1007/s13555-024-01105-3},
}
Figure